0001437749-14-021372.txt : 20141125 0001437749-14-021372.hdr.sgml : 20141125 20141125162626 ACCESSION NUMBER: 0001437749-14-021372 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141020 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20141125 DATE AS OF CHANGE: 20141125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 141249936 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 8-K/A 1 pdli20141125_8ka.htm FORM 8-K/A pdli20141125_8ka.htm

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): October 20, 2014

 

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

 

000-19756

(Commission

File Number)

 

     

Delaware

 

94-3023969

(State or Other Jurisdiction

of Incorporation)

 

(I.R.S. Employer

Identification No.)

 

932 Southwood Boulevard

Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

 

(775) 832-8500

(Company’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 
 

 

Explanatory Note

 

This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed by PDL BioPharma, Inc. (the Company) on October 22, 2014 (the Original 8-K). The Company is amending the Original 8-K for the purpose of disclosing the completion of the transaction and providing the number of shares issued and the amount of the cash payment made in connection therewith. Pursuant to the terms of the exchange agreement referenced in Item 1.01 of the Original 8-K, the Company issued 1,809,281 shares of its common stock and made a cash payment of $26,181,431.25 in exchange for the retirement of $25,974,000 in principal amount of the Company’s 2.875% Series 2012 Convertible Senior Notes.

 

 
 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     

PDL BIOPHARMA, INC.

(Company)

   

By:

 

/s/ Peter S. Garcia

 

 

Peter S. Garcia

 

 

Vice President and Chief Financial Officer

 

Dated: November 25, 2014